---
title: 'Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma
  is associated with survival outcomes: A multicenter cohort study'
date: '2024-10-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39377358/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241008201240&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: MYC(N)-amplified MB displays significant clinicobiological
  heterogeneity. Diagnostics incorporating molecular groups, subgroups, and clinical
  factors enable their risk assessment. VHR "canonical" MYC tumors are essentially
  incurable and SHH-MYCN-amplified MBs fare extremely poorly (20% survival at 5 years);
  both require urgent development of alternative treatment strategies. Conventional
  risk-adapted therapies are appropriate for more responsive groups, such as noncanonical
  MYC ...'
disable_comments: true
---
CONCLUSIONS: MYC(N)-amplified MB displays significant clinicobiological heterogeneity. Diagnostics incorporating molecular groups, subgroups, and clinical factors enable their risk assessment. VHR "canonical" MYC tumors are essentially incurable and SHH-MYCN-amplified MBs fare extremely poorly (20% survival at 5 years); both require urgent development of alternative treatment strategies. Conventional risk-adapted therapies are appropriate for more responsive groups, such as noncanonical MYC ...